Daratumumab Plus Len-Dex Induces Rapid, Durable Responses

Share this content:
Daratumumab in combination with lenalidomide and dexamethasone induced durable responses in patients relapsed/refractory multiple myeloma.
Daratumumab in combination with lenalidomide and dexamethasone induced durable responses in patients relapsed/refractory multiple myeloma.

Daratumumab in combination with lenalidomide and dexamethasone induced rapid, deep, durable responses and was well-tolerated in patients relapsed/refractory multiple myeloma, a study published in Blood has shown.1

Because single-agent daratumumab has activity in relapsed/refractory multiple myeloma, researchers sought to investigate the activity and safety of the human CD38 IgG1κ monoclonal antibody plus lenalidomide and dexamethasone in a phase 1/2 study.

In part 1, 4 doses of daratumumab in that combination were evaluated in 13 patients. No dose-limiting toxicities were observed, and thus, the 16 mg/kg dose was selected as the recommended phase 2 dose.

In phase 2, 32 patients with relapsed/refractory multiple myeloma were enrolled. The median time since diagnosis was 3.2 years and patients had a received a median of 2 prior therapies.

After a median follow-up of 15.6 months, 81% of patients had achieved a response, with 8 patients achieving stringent complete responses and 3 having complete responses; 9 patients achieved very good partial responses.

The 18-month progression-free survival and overall survival rates were 72% (95% CI, 51.7-85.0) and 90% (95% CI, 73.1-96.8), respectively.

RELATED: In Search of the Right Treatment Combinations for Multiple Myeloma

The most frequently reported grade 3 to 4 adverse events included neutropenia, thrombocytopenia, and anemia. Infusion-related reactions, which were mostly grade 2 or less, occurred in 56% of the 32 patients in the phase 2 portion.

Reference

  1. Plesner T, Arkenau H-T, Gimsing P, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016 Aug 16. doi: 10.1182/blood-2016-07-726729. [Epub ahead of print] 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs